1- Gatti, A., Lazzari, M., Gianfelice, V., Di Paolo, A., Sabato, E., & Sabato, A. F. (2012). Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Medicine, 13(9), 1121-1130.
2- Einaudi, V. L., & Varrassi, G. (2016). Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain physician, 19(2), 11-24.
3- Ahmad, A., Crupi, R., Impellizzeri, D., Campolo, M., Marino, A., Esposito, E., & Cuzzocrea, S. (2012). Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain, behavior, and immunity, 26(8), 1310-1321.
4- Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N. O., Leonova, J., … & Greasley, P. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. British journal of pharmacology, 152(7), 1092-1101.
5- Paterniti, I., Impellizzeri, D., Crupi, R., Morabito, R., Campolo, M., Esposito, E., & Cuzzocrea, S. (2013). Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. Journal of neuroinflammation, 10(1), 1-13.
6- Ambrosino, P., Soldovieri, M. V., Russo, C., & Taglialatela, M. (2013). Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. British Journal of Pharmacology, 168(6), 1430-1444.
7- Romero, T. R. L., & Duarte, I. D. G. (2012). N-palmitoyl-ethanolamine (PEA) induces peripheral antinociceptive effect by ATP-sensitive K+-channel activation. Journal of pharmacological sciences, 118(2), 156-160.
8-Brown, J. M., Wilson, T. M., & Metcalfe, D. D. (2008). The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clinical & Experimental Allergy, 38(1), 4-18.
9-Petrosino, S., Schiano Moriello, A., Cerrato, S., Fusco, M., Puigdemont, A., De Petrocellis, L., & Di Marzo, V. (2016). The anti‐inflammatory mediator palmitoylethanolamide enhances the levels of 2‐arachidonoyl‐glycerol and potentiates its actions at TRPV1 cation channels. British Journal of Pharmacology, 173(7), 1154-1162.
10-Suzuki, K. (2019). Chronic inflammation as an immunological abnormality and effectiveness of exercise. Biomolecules, 9(6), 223.
11-D’Agostino, G., La Rana, G., Russo, R., Sasso, O., Iacono, A., Esposito, E., … & Calignano, A. (2009). Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-κB nuclear signalling in dorsal root ganglia. European journal of pharmacology, 613(1-3), 54-59.
12-Bettoni, I., Comelli, F., Colombo, A., Bonfanti, P., & Costa, B. (2013). Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 12(1), 34-44.
13-Dalla Volta, G., Zavarize, P., Ngonga, G. K., & Carli, D. (2016). Ultramicronized palmitoylethanolamide reduces frequency and pain intensity in migraine. A pilot study. Int J Neurol Brain Dis, 3, 1-5.
14-Tartaglia, E., Armentano, M., Giugliano, B., Sena, T., Giuliano, P., Loffredo, C., & Mastrantonio, P. (2015). Effectiveness of the association N-palmitoylethanolamine and transpolydatin in the treatment of primary dysmenorrhea. Journal of Pediatric and Adolescent Gynecology, 28(6), 447-450.
15-Del Giorno, R., Skaper, S., Paladini, A., Varrassi, G., & Coaccioli, S. (2015). Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain and therapy, 4, 169-178.
16-Marini, I., Lavinia Bartolucci, M., Bortolotti, F., Rosaria Gatto, M., & Alessandri Bonetti, G. (2012). Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. Journal of orofacial pain, 26(2), 99.
17-Steels, E., Venkatesh, R., Steels, E., Vitetta, G., & Vitetta, L. (2019). A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology, 27, 475-485.
18-Bronzuoli, M. R., Facchinetti, R., Romano, A., Stecca, C., Passarella, S., Steardo, L., … & Scuderi, C. (2018). Palmitoylethanolamide dampens reactive astrogliosis and improves neuronal trophic support in a triple transgenic model of Alzheimer’s disease: in vitro and in vivo evidence. Oxidative medicine and cellular longevity, 2018.
19-Beggiato, S., Tomasini, M. C., & Ferraro, L. (2019). Palmitoylethanolamide (PEA) as a potential therapeutic agent in Alzheimer’s disease. Frontiers in pharmacology, 10, 821.
20-Cordaro, M., Impellizzeri, D., Paterniti, I., Bruschetta, G., Siracusa, R., De Stefano, D., … & Esposito, E. (2016). Neuroprotective effects of Co-ultraPEALut on secondary inflammatory process and autophagy involved in traumatic brain injury. Journal of neurotrauma, 33(1), 132-146.
21-Brotini, S., Schievano, C., & Guidi, L. (2017). Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson’s disease. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 16(6), 705-713.
22-Roviezzo, F., Rossi, A., Caiazzo, E., Orlando, P., Riemma, M. A., Iacono, V. M., … & Izzo, A. A. (2017). Palmitoylethanolamide supplementation during sensitization prevents airway allergic symptoms in the mouse. Frontiers in Pharmacology, 8, 857.
23-Cerrato, S., Brazis, P., Della Valle, M. F., Miolo, A., Petrosino, S., Di Marzo, V., & Puigdemont, A. (2012). Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. The Veterinary Journal, 191(3), 377-382.
24-Scarampella, F., Abramo, F., & Noli, C. (2001). Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Veterinary dermatology, 12(1), 29-39.
25-Noli, C., Della Valle, M. F., Miolo, A., Medori, C., Schievano, C., & Skinalia Clinical Research Group. (2015). Efficacy of ultra‐micronized palmitoylethanolamide in canine atopic dermatitis: an open‐label multi‐centre study. Veterinary dermatology, 26(6), 432-e101.
26-Rankin, L., & Fowler, C. J. (2020). The basal pharmacology of palmitoylethanolamide. International Journal of Molecular Sciences, 21(21), 7942.
27-Gabrielsson, L., Mattsson, S., & Fowler, C. J. (2016). Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. British journal of clinical pharmacology, 82(4), 932-942
28- Clayton, P., Subah, S., Venkatesh, R., Hill, M., & Bogoda, N. (2023). Palmitoylethanolamide: A potential alternative to cannabidiol. Journal of dietary supplements, 20(3), 505-530.
Valoraciones
No hay valoraciones aún.